Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Year: 2010
Type: article
Abstract: On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.
Source: New England Journal of Medicine
DOI: 10.1056/nejmp1001578
Authors: Mary Parks, Curtis Rosebraugh
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2058922633
